Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
02
2023
accepted:
16
05
2023
medline:
7
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
epublish
Résumé
A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0-1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA. In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.
Identifiants
pubmed: 37656725
doi: 10.1371/journal.pone.0286479
pii: PONE-D-23-03053
pmc: PMC10473486
doi:
Substances chimiques
Ebola Vaccines
0
Blood Group Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0286479Informations de copyright
Copyright: © 2023 Zola Matuvanga et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):82-87
pubmed: 32859866
Mem Inst Oswaldo Cruz. 2016 Jul 4;111(8):501-4
pubmed: 27384081
PLoS One. 2020 Apr 27;15(4):e0230406
pubmed: 32339195
Lancet Infect Dis. 2021 Apr;21(4):507-516
pubmed: 33065039
PLoS Pathog. 2015 Nov 12;11(11):e1005221
pubmed: 26562671
Emerg Infect Dis. 2022 Mar;28(3):734-738
pubmed: 35202536
Emerg Infect Dis. 2019 May;25(5):911-918
pubmed: 31002071
J Infect Dis. 1999 Feb;179 Suppl 1:S259-62
pubmed: 9988192
Qual Assur. 2003 Apr-Jun;10(2):83-9
pubmed: 14660298
PLoS One. 2014 Jun 10;9(6):e96360
pubmed: 24914933
Virol Sin. 2021 Dec;36(6):1648-1651
pubmed: 34152565
N Engl J Med. 2014 Nov 27;371(22):2083-91
pubmed: 25317743
PLoS Negl Trop Dis. 2021 Aug 12;15(8):e0009566
pubmed: 34383755
J Infect Dis. 2022 Aug 24;226(2):352-356
pubmed: 35176762
J Virol Methods. 2018 May;255:84-90
pubmed: 29481881
Lancet. 2022 May 7;399(10337):1766
pubmed: 35526542
Arch Virol Suppl. 2008;20:13-360
pubmed: 18637412
PLoS One. 2019 Apr 18;14(4):e0215457
pubmed: 30998735
Int J Infect Dis. 2022 Feb;115:126-133
pubmed: 34883237
J Infect Dis. 2018 Jan 4;217(2):223-231
pubmed: 29253164
BMC Infect Dis. 2016 Jun 10;16:263
pubmed: 27286990
Clin Infect Dis. 2016 Nov 15;63(10):1353-1356
pubmed: 27585800
Bull World Health Organ. 1978;56(2):271-93
pubmed: 307456
J Clin Microbiol. 2016 Dec 28;55(1):165-176
pubmed: 27795350
J Infect Dis. 2018 Jan 30;217(4):529-537
pubmed: 29329455
Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721):
pubmed: 28396474
PLoS Negl Trop Dis. 2011 Jun;5(6):e1175
pubmed: 21666792
Curr Protoc Microbiol. 2009 May;Chapter 1:Unit 1A.1
pubmed: 19412909
PLoS Negl Trop Dis. 2015 Jun 05;9(6):e0003833
pubmed: 26047124
Lancet Infect Dis. 2019 Mar;19(3):308-316
pubmed: 30765243
BMJ Open. 2021 Sep 28;11(9):e046835
pubmed: 34588237
Sci Adv. 2018 Nov 07;4(11):eaat2993
pubmed: 30417092
J Infect Dis. 1999 Feb;179 Suppl 1:S102-7
pubmed: 9988172
J Infect Dis. 2022 Sep 4;226(4):608-615
pubmed: 33269402
J Infect Dis. 2019 Jan 29;219(4):517-525
pubmed: 30239838
PLoS Negl Trop Dis. 2016 Nov 15;10(11):e0005087
pubmed: 27846221
Bull World Health Organ. 1978;56(2):247-70
pubmed: 307455
PLoS Negl Trop Dis. 2022 Mar 7;16(3):e0010167
pubmed: 35255093
Emerg Infect Dis. 2020 Sep;26(9):2205-2209
pubmed: 32818404
Lancet Microbe. 2021 Dec;2(12):e676-e684
pubmed: 35544108
J Infect Dev Ctries. 2015 May 18;9(5):441-55
pubmed: 25989163
J Infect Dis. 1999 Feb;179 Suppl 1:S192-8
pubmed: 9988184
Emerg Infect Dis. 2009 Jul;15(7):1136-7
pubmed: 19624943
J Virol Methods. 2021 Nov;297:114228
pubmed: 34224754